Sionna Therapeutics announced it will start a Phase 2 trial in early 2027 for its dual cystic fibrosis drug combination SION-451 + SION-2222, following positive Phase 1 results and supportive clinical data. The trial will test safety and efficacy in patients switching from Trikafta®. Despite a workforce cut of 46%, the company maintains a strong cash position of $249.8 million, expected to fund operations into late 2029. This advancement aims to offer new treatment options for people with cystic fibrosis by stabilizing the CFTR protein function.
Sionna Therapeutics holds a strong cash position of $249.8 million as it prepares to start a Phase 2 trial in early 2027 for its cystic fibrosis drug combination. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 priced US health stocks, 85 rose and 56 fell. Notable movers include Revvity Inc (RVTY) at USD 163.18 with a 1-day change of +1.53% and 100% sell order activity, LifeStance Health Group Inc. (LFST) at USD 14.81 with +1.44%, and Enveric Biosciences Inc (ENVB) at USD 1.46 with +1.39%.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
